IRVINE, CA--(Marketwired - January 10, 2014) -
ChromaDex® Corporation (OTCQB: CDXC
) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, is pleased to announced the archive of CEO Frank Jaksch's recent live interview by Michal Yorba on Clear Channel Business Talk Radio's "The Traders Network."
On the heels of ChromaDex's recently announced $62 million ingredient supply and brand licensing agreement with 5LINX® for Chromadex's NIAGEN™ nicotinamide riboside and PURENERGY™, CEO and founder Frank Jaksch delivered a captivating interview covering the Company's unique business model as well as the characteristics that makes its portfolio of patented ingredients compelling to both industry players and investors alike.
In the interview, Jaksch said, "ChromaDex is currently commercialization four patented and proprietary ingredient technologies which address large multibillion dollar markets. NIAGEN™ is our brand for the compound nicotinamide riboside, to be referred to as 'NR.' It is closely related to a metabolite of the B vitamin known as Niacin. It is well known for its significant health benefits as well as for being included in many different types of products. There is a common side effect with Niacin -- if you take too much you get a flush effect, and it makes people feel pretty uncomfortable. Our version NR is actually a 'no flush' version of Niacin that also has more pronounced health benefits largely on increasing NAD+ than Niacin even does. NR is probably the most potent precursor to NAD+, and there has been a lot of activity recently around the importance of NAD+ to energy metabolism, and profound effects that the compound has on aging. NIAGEN™ is a precursor to NAD+ and it has significant effects on improving mitochondrial population. Mitochondria, the energy center of everyone's cellular processes, are the link to the aging process or age related disease. There was a publication at the end of December by David Sinclair of Harvard Medical School that showed that NAD+, or improving NAD+, can actually reverse the effects of aging, which is one of the first publications that showed something along those lines."
"Our PURENERGY™ is a caffeine alternative, and everybody is aware of the problems right now in the energy beverage category which is under pressure regarding health concerns for heavily-caffeinated products. We put PURENERGY™ into a human study and we proved that you can deliver more caffeine, more efficiently into the blood then caffeine on its own, which means that you can reduce the amount of caffeine by up to or over 50% without losing the customer expectation -- that experience that they want from the caffeine, but with a vastly reduced amount of caffeine."
Jaksch also highlighted that "ChromaDex is a leader in providing a seamless suite of natural products chemistry and science-based solutions to large, Fortune 500 companies such as Coca Cola, Kraft Foods, Nestle and Abbott Labs."
To hear the entire Clear Channel Interview with CEO Frank Jaksch, please visit the archive link below:
Interview Archive (12 min, 48 sec) http://www.yorbamedia.com/images/stories/audio/TN010614SEG4.mp3
Network: Clear Channel & iHeart Radio
Station: DFW 1190AM
Host: Michael Yorba
Michael Yorba, Clear Channel host of the Traders Network Show, was quoted saying, "an awesome company doing awesome things!"
About Clear Channel
Clear Channel Media and Entertainment's more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country. DFW1190AM.com Dallas-Ft. Worth, TX www.clearchannel.com
About Michael Yorba
Michael Yorba -- featured host of Clear Channels DFW 1190AM in Dallas-Ft.Worth. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on Internet television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex. www.yorbamedia.com.
ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
A www.1800PublicRelations.com PR Event
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.